| Autor: |
Garin AM, Gorbunova VA, Gershanovich ML, Manziuk LV, Borodkina AG, Breder VV, Karmanovskaia OB, Zubrikhina GN, Madzhuga AV, Zimakova NI, Trapeznikov NN |
| Jazyk: |
ruština |
| Zdroj: |
Voprosy onkologii [Vopr Onkol] 2001; Vol. 47 (6), pp. 676-9. |
| Abstrakt: |
Phase-I clinical studies of teraphtal and a "teraphtal + ascorbic acid" catalytic system have been completed. The dose-limiting toxicity and maximum tolerable dose were not reached even at the end of maximal dose trials. No side-effects characteristic of antitumor cytostatic drugs were registered. The gravest side-effect ever recorded was a collapse which could not be linked to teraphtal dosage and was probably caused by hypersensitivity to the drug. The drug was recommended for phase II trials. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
